481411
NF-κB Activation Inhibitor III
The NF-κB Activation Inhibitor III, also referenced under CAS 380623-76-7, controls the biological activity of NF-κB. This small molecule/inhibitor is primarily used for Inflammation/Immunology applications.
别名:
NF-κB Activation Inhibitor III, 3-Chloro-4-nitro-N-(5-nitro-2-thiazolyl)-benzamide, SM-7368
登录查看公司和协议定价
所有图片(1)
About This Item
推荐产品
品質等級
化驗
≥98% (HPLC)
形狀
amorphous solid
製造商／商標名
Calbiochem®
儲存條件
OK to freeze
protect from light
顏色
light yellow
溶解度
DMSO: 10 mg/mL
運輸包裝
ambient
儲存溫度
2-8°C
InChI
1S/C10H5ClN4O5S/c11-6-3-5(1-2-7(6)14(17)18)9(16)13-10-12-4-8(21-10)15(19)20/h1-4H,(H,12,13,16)
InChI 密鑰
XCHLNGBTHLJLFG-UHFFFAOYSA-N
一般說明
A cell-permeable inhibitor of TNF-α-stimulated NF-κB activation and subsequent upregulation of MMP-9 in HT1080 cells (complete inhibition at 10 µM). The inhibition of MMP-9 upregulation correlates with a concomitant inhibition of TNF-α-dependent cell invasion. Does not affect TNF-α-induced AP-1 activity. The cellular target appears to be downstream of p38 activation.
A cell-permeable thiazoloamide compound that inhibits TNF-α-stimulated NF-κB activation and subsequent upregulation of MMP-9 in HT1080 cells (complete inhibition at 10 µM). The inhibition of MMP-9 upregulation correlates with a concomitant inhibition of TNF-α-dependent cell invasion. Does not affect TNF-α-induced AP-1 activity. The cellular target appears to be downstream of p38 activation.
生化／生理作用
Cell permeable: yes
Effective concentration: 10 µM for complete inhibition of TNF-α-stimulated NF-κB activation and subsequent upregulation of MMP-9 in HT1080 cells
Primary Target
TNF-α-stimulated NF-κB activation and upregulation of MMP-9
TNF-α-stimulated NF-κB activation and upregulation of MMP-9
Product does not compete with ATP.
Reversible: no
包裝
Packaged under inert gas
警告
Toxicity: Irritant (B)
其他說明
Lee, H.Y., et al. 2005. Biochem. Biophys. Res. Commun.336, 716.
法律資訊
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
Mohamed Hassan et al.
Oncology letters, 25(1), 41-41 (2023-01-03)
Topoisomerase inhibitors are clinically used to treat various cancer types, including colorectal cancer. These drugs also activate signaling pathways that modulate cell survival and immune cell functions. Immunotherapy is promising for certain tumors, including microsatellite instable colorectal cancer, but not
Mari E Strand et al.
Journal of molecular and cellular cardiology, 88, 133-144 (2015-10-10)
Inflammation is central to heart failure progression. Innate immune signaling increases expression of the transmembrane proteoglycan syndecan-4 in cardiac myocytes and fibroblasts, followed by shedding of its ectodomain. Circulating shed syndecan-4 is increased in heart failure patients, however the pathophysiological
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门